You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

icans

Showing 251 - 273 of 273
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Multiple Myeloma Trial in Sanhe (BCMA/CD19 dual-target CAR-T cell immunotherapy)

Not yet recruiting
  • Multiple Myeloma
  • BCMA/CD19 dual-target CAR-T cell immunotherapy
  • Sanhe, Hebei, China
    Hebei Yanda Ludaopei Hospital
Jun 1, 2020

Prostate Cancer Metastatic Trial in France (Darolutamide 300 mg, Placebo, Androgen deprivation therapy)

Recruiting
  • Prostate Cancer Metastatic
  • Darolutamide 300 mg
  • +2 more
  • Avignon, France
  • +44 more
Sep 28, 2022

Upper Tract Urothelial Carcinomas, Urothelial Bladder Cancer Trial in Worldwide (Infigratinib, Placebo)

Recruiting
  • Upper Tract Urothelial Carcinomas
  • Urothelial Bladder Cancer
  • Tucson, Arizona
  • +133 more
Apr 25, 2022

Squamous Cell Carcinoma of the Head and Neck Trial in Worldwide (Xevinapant (Debio 1143), Cisplatin, Intensity Modulation

Recruiting
  • Squamous Cell Carcinoma of the Head and Neck
  • Xevinapant (Debio 1143)
  • +3 more
  • Gilbert, Arizona
  • +280 more
Aug 22, 2022

Metastatic Hormone-Sensitive Prostate Cancer Trial in Worldwide (biological, drug, procedure, other)

Active, not recruiting
  • Metastatic Hormone-Sensitive Prostate Cancer
  • Pembrolizumab
  • +3 more
  • Anchorage, Alaska
  • +212 more
Aug 18, 2022

Breast Tumors, Tumor Metastasis Trial in Worldwide (Imlunestrant, Exemestane, Fulvestrant)

Recruiting
  • Breast Neoplasms
  • Neoplasm Metastasis
  • Chandler, Arizona
  • +238 more
Aug 17, 2022

B-cell Non Hodgkin Lymphoma Trial in Sanhe (GC022F)

Not yet recruiting
  • B-cell Non Hodgkin Lymphoma
  • GC022F
  • Sanhe, Hebei, China
    Hebei Yanda Ludaopei Hospital
Jun 1, 2020

Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia, Non-Hodgkin's Lymphoma Refractory, Non-Hodgkin's Lymphoma, Relapsed

Recruiting
  • Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
  • +2 more
  • Autologous CAR19 T lymphocytes
  • Prague, Czechia
    Institute of Hematology and Blood Transfusion, Czech Republic
Aug 3, 2022

Cancer, Malignancy, Refractory Cancer Trial in Singapore (Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted ?d T

Not yet recruiting
  • Cancer
  • +3 more
  • Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells (CTM-N2D)
  • Singapore, Singapore
    National University Hospital
Mar 20, 2022

Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS) Trial in United States (Infusion of NEXI-001 T Cells)

Recruiting
  • Acute Myeloid Leukemia (AML)
  • Myelodysplastic Syndrome (MDS)
  • Infusion of NEXI-001 T Cells
  • Duarte, California
  • +4 more
Feb 16, 2021

Prostate Cancer Trial in Worldwide (talazoparib plus enzalutamide, Placebo plus enzalutamide)

Recruiting
  • Prostate Cancer
  • talazoparib plus enzalutamide
  • Placebo plus enzalutamide
  • Birmingham, Alabama
  • +306 more
Jan 18, 2023

Colorectal Cancer Trial in Worldwide (Cetuximab, FOLFOX induction regimen, Fluoropyrimidine (5-FU/LV or capecitabine))

Completed
Has Results
  • Colorectal Cancer
  • Buenos Aires, Argentina
  • +154 more
May 3, 2021

Clear Cell Renal Cell Carcinoma Trial in Worldwide (Belzutifan, Pembrolizumab, Placebo)

Recruiting
  • Clear Cell Renal Cell Carcinoma
  • Duarte, California
  • +250 more
Jan 27, 2023

Pancreas Adenocarcinoma Trial in Worldwide (NovoTTF-100L(P), Gemcitabine, nab paclitaxel)

Recruiting
  • Pancreas Adenocarcinoma
  • NovoTTF-100L(P)
  • +2 more
  • Birmingham, Alabama
  • +145 more
Aug 10, 2022

mCRPC Trial in Worldwide (Talazoparib with enzalutamide, Placebo with enzalutamide)

Active, not recruiting
  • mCRPC
  • Talazoparib with enzalutamide
  • Placebo with enzalutamide
  • Anchorage, Alaska
  • +363 more
Aug 3, 2022

Multiple Myeloma Trial in Xi'an (BCMA/CD19 Dual-Target CAR-T)

Unknown status
  • Multiple Myeloma
  • BCMA/CD19 Dual-Target CAR-T
  • Xi'an, Shanxi, China
    First affiliated hospital of air force military medical universi
Nov 27, 2019

Tumors Trial in United States (letetresgene autoleucel (GSK3377794), Cyclophosphamide, Fludarabine)

Completed
Has Results
  • Neoplasms
  • letetresgene autoleucel (GSK3377794)
  • +2 more
  • Tampa, Florida
  • +5 more
Oct 31, 2022

Leukemia Relapse in the CNS Treated With CAR T Cells

Unknown status
  • Acute Lymphoblastic Leukemia
    • Ramat Gan, Israel
      Chaim Sheba Medical Center
    Nov 7, 2019

    Colorectal Cancer Metastatic, High Immune Infiltrate, Microsatellite Stable Trial in France (Capecitabine, Oxaliplatin,

    Recruiting
    • Colorectal Cancer Metastatic
    • +2 more
    • Abbeville, France
    • +87 more
    Mar 23, 2022

    NSCLC Metastatic, Breast Cancer Female, Colon Cancer Trial in Strasbourg (Adaptated Physical Activity)

    Unknown status
    • Non-small Cell Lung Cancer Metastatic
    • +2 more
    • Adaptated Physical Activity
    • Strasbourg, France
      Centre Paul Strauss
    Feb 10, 2020

    Squamous Cell Carcinoma of the Head and Neck Trial in Worldwide (Avelumab, Chemoradiation)

    Terminated
    Has Results
    • Squamous Cell Carcinoma of the Head and Neck
    • Fayetteville, Arkansas
    • +315 more
    Sep 20, 2021

    Non-small-cell Lung Cancer Trial in France (Pembrolizumab, Pembrolizumab and Chemotherapy drugs)

    Recruiting
    • Non-small-cell Lung Cancer
    • Aix-en-Provence, France
    • +30 more
    Mar 10, 2021

    Lymphomas Non-Hodgkin's B-Cell, Diffuse Large B-cell Lymphoma (DLBCL), Primary Mediastinal B-cell Lymphoma (PMBCL) Trial in

    Recruiting
    • Lymphomas Non-Hodgkin's B-Cell
    • +5 more
    • WZTL002-1 (1928T2z CAR-T cells)
    • Cyclophosphamide and Fludarabine lymphodepleting chemotherapy
    • Wellington, New Zealand
      Wellington Hospital, Capital & Coast District Health Board
    Feb 18, 2020